| 1 |
Hehlmann R. Innovation in hematology. Perspectives: CML 2016 [J]. Haematologica, 2016, 101(6): 657-659.
|
| 2 |
Sweetman SC. The complete drug reference. 36th ed. London: Press UK.
|
| 3 |
Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate [J]. J Drugs Dermatol, 2006, 5(3): 228-231.
|
| 4 |
杨敏, 常建民. 伊马替尼引起的皮肤不良反应 [J].中华皮肤科杂志, 2021, 54(8): 738-741.
|
| 5 |
祝洪梅. 224例甲磺酸伊马替尼不良反应文献分析 [J]. 中国药物警戒, 2018, 15(12): 733-737.
|
| 6 |
Lee WJ, Lee JH, Won CH, et al. Clinical and histopathologic analysis of 46 cases of cutaneous adverse reactions to imatinib [J]. Int J Dermatol, 2016, 55(5): e268-e274.
|
| 7 |
Vinay K, Yanamandra U, Dogra S, et al. Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients [J]. Int J Dermatol, 2018, 57(3): 332-338.
|
| 8 |
Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia [J]. N Engl J Med, 2017, 376(10): 917-927.
|
| 9 |
Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia [J]. N Engl J Med, 2010, 362(24): 2260-2270.
|
| 10 |
Vener C, Banzi R, Ambrogi F, et al. First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis [J]. Blood Adv, 2020, 4(12): 2723-2735.
|
| 11 |
Nakamae H, Fujisawa S, Ogura M, et al. Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report [J]. Int J Hematol, 2017, 105(6): 792-804.
|